SUMMARY
Once again, this year, the ASH Congress provided a wealth of information on myeloproliferative neoplasms (MPNs). In the field of classical Phi-negative MPNs, studies that could potentially influence our practice in the short and medium terms, with a focus on molecular responses and disease modification were selected. In the field of chronic myeloid leukaemia, studies providing additional information on Asciminib as well as strategies to improve the TFR rate in patients were selected. Finally, a study with promising results in the field of MDS/MDN overlap syndromes and chronic neutrophilic leukaemia was included.
(BELG J HEMATOL 2024;15(1):9–12)
